Search Contract Opportunities

Chemistry, Manufacturing and Controls and Related Services for Development of Drug Products

ID: 75N95025R00005 • Type: Synopsis Solicitation
Opportunity Assistant

Hello! Please let me know your questions about this opportunity. I will answer based on the available opportunity documents.

Please sign-in to link federal registration and award history to assistant. Sign in to upload a capability statement or catalogue for your company

Some suggestions:
Please summarize the work to be completed under this opportunity
Do the documents mention an incumbent contractor?
Does this solicitation list any subcontracting requirements?
I'd like to anonymously submit a question to the procurement officer(s)
Loading

Description

The Therapeutic Development Branch (TDB) within the Division of Preclinical Innovation (DPI) at the National
Center for Advancing Translational Sciences (NCATS) conducts translational research in the area of human
therapeutics development.

The scope of this contract is for Chemistry, Manufacturing, and Control (CMC) services for Drug Products. The
objective of these support services is to ensure receipt of formulated Drug Product (DP) of sufficient quality and quantity to support preclinical, IND-enabling and clinical studies.

The Contractor shall provide support for a broad range of preclinical services required for the design, development,
manufacture, and release of DP, and release of DP as Clinical Trial Material (CTM), including precursors, preliminary
states, Reference Standards (RS) and all required testing. Ancillary products (e.g., placebos, diluents, adjuvants,
master cell banks, testing standards, reference materials) and other materials manufactured or purchased to
support clinical trials or CMC activities may also be required. All activities preliminary to manufacturing in
accordance with current Good Manufacturing Practice (cGMP) may be required (e.g., development or engineering
lots, formulation studies), even without an associated cGMP manufacturing task. All activities required to maintain
material in a usable state, including storage, shipping, testing (in process, release, stability, and quality actions),
and preparation of documents to support regulatory submissions may also be required.

Product formats may include small molecules, short oligomeric compounds, biological (large) molecules,
quaternary molecular assemblies (homogenous or heterogenous), vectors for gene therapy, nanoparticles, and any
of the above modified genetically, biologically, or chemically. Novel formats identified after this draft might also be
needed. Formats could also include Devices or Combination Products. The breadth of this Statement of Work (SOW) includes capabilities to support a range of activities differing in size,
complexity, and duration.

All applicable attachments in connection with this solicitation are available for download.

Background
The Therapeutic Development Branch (TDB) within the Division of Preclinical Innovation (DPI) at the National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health (NIH), conducts translational research aimed at advancing human therapeutics development.

The TDB's mission includes moving small molecule and biologic drug candidates through the drug development pipeline, ultimately filing Investigational New Drug (IND) applications with the FDA. The goal of this contract is to provide Chemistry, Manufacturing, and Control (CMC) services for Drug Products to ensure that formulated Drug Products (DP) meet quality and quantity standards necessary for preclinical, IND-enabling, and clinical studies.

Work Details
The Contractor shall provide a broad range of preclinical services required for the design, development, manufacture, and release of Drug Products as Clinical Trial Material (CTM). This includes:
- Support for formulation development studies and defining final formulations.
- Conducting pre-formulation studies based on targeted dosage forms.
- Performing technology transfer from collaborators.
- Manufacturing non-GMP Drug Products in quantities necessary for preclinical studies (typically 500 to 5,000 units).
- Manufacturing GMP Drug Products in quantities to support clinical studies (typically 1,000 to 10,000 units).
- Developing necessary in-process control methods and validating analytical methods.
- Conducting stability studies up to 24 months per ICH guidelines.
- Preparing documents to support regulatory submissions including certificates of analysis (COA).
- Maintaining compliance with current Good Manufacturing Practices (cGMP) throughout all activities.

Overview

Response Deadline
Feb. 3, 2025, 3:00 p.m. EST Past Due
Posted
Nov. 30, 2024, 4:24 p.m. EST (updated: Jan. 14, 2025, 1:45 p.m. EST)
Set Aside
None
Place of Performance
Rockville, MD 20850 United States
Source
SAM

Current SBA Size Standard
1300 Employees
Pricing
Multiple Types Common
Est. Level of Competition
Low
Est. Value Range
Experimental
$5,000,000 - $20,000,000 (AI estimate)
Vehicle Type
Indefinite Delivery Contract
On 11/30/24 National Institute on Drug Abuse issued Synopsis Solicitation 75N95025R00005 for Chemistry, Manufacturing and Controls and Related Services for Development of Drug Products due 2/3/25. The opportunity was issued full & open with NAICS 325412 and PSC AN12.
Primary Contact
Name
Michelle Cecilia   Profile
Phone
(301) 827-7199

Secondary Contact

Name
Valerie Whipple   Profile
Phone
(301) 827-5218

Documents

Posted documents for Synopsis Solicitation 75N95025R00005

Question & Answer

The AI Q&A Assistant has moved to the bottom right of the page

Incumbent or Similar Awards

Contracts Similar to Synopsis Solicitation 75N95025R00005

Potential Bidders and Partners

Awardees that have won contracts similar to Synopsis Solicitation 75N95025R00005

Similar Active Opportunities

Open contract opportunities similar to Synopsis Solicitation 75N95025R00005

Additional Details

Source Agency Hierarchy
HEALTH AND HUMAN SERVICES, DEPARTMENT OF > NATIONAL INSTITUTES OF HEALTH > NATIONAL INSTITUTES OF HEALTH NIDA
FPDS Organization Code
7529-75N950
Source Organization Code
100189048
Last Updated
Feb. 18, 2025
Last Updated By
michellececilia.cecilia@nih.gov
Archive Date
Feb. 18, 2025